Julie Winkler - CME Managing Director
| CME Stock | USD 229.37 0.33 0.14% |
Managing Director
Ms. Julie Winkler is Senior Managing Director, Chief Commercial Officer of the Company. Ms. Winkler has served as our Senior Managing Director, Chief Commercial Officer since December 2016. She previously served as Senior Managing Director, Research and Product Development and Index Services of CME Group since 2014 and as Managing Director, Research and Product Development since 2007. Prior to our merger with CBOT Holdings, Ms. Winkler held positions of increasing responsibility for CBOT Holdings since 1996. Ms. Winkler also serves as a director of SPDow Jones Indices LLC. since 2016.
| Age | 49 |
| Tenure | 8 years |
| Address | 20 South Wacker Drive, Chicago, IL, United States, 60606 |
| Phone | 312 930 1000 |
| Web | https://www.cmegroup.com |
Julie Winkler Latest Insider Activity
Tracking and analyzing the buying and selling activities of Julie Winkler against CME stock is an integral part of due diligence when investing in CME. Julie Winkler insider activity provides valuable insight into whether CME is net buyers or sellers over its current business cycle. Note, CME insiders must abide by specific rules, including filing SEC forms every time they buy or sell CME'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Julie Winkler over a year ago Acquisition by Julie Winkler of 3808 shares of CME subject to Rule 16b-3 | ||
Julie Winkler over a year ago Payment of 1513 shares by Julie Winkler of CME subject to Rule 16b-3 |
CME Management Efficiency
The company has Return on Asset of 0.0184 % which means that on every $100 spent on assets, it made $0.0184 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.123 %, implying that it generated $0.123 on every 100 dollars invested. CME's management efficiency ratios could be used to measure how well CME manages its routine affairs as well as how well it operates its assets and liabilities. At present, CME's Return On Capital Employed is projected to increase slightly based on the last few years of reporting. The current year's Return On Assets is expected to grow to 0.03, whereas Return On Equity is forecasted to decline to 0.12. At present, CME's Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 95.9 B, whereas Other Assets are forecasted to decline to about 127.7 M.Similar Executives
| Found 2 records | MANAGING DIRECTOR Age | ||
| Theodore Niggli | MSCI Inc | N/A | |
| Remy Briand | MSCI Inc | 58 | |
Management Performance
| Return On Equity | 0.12 | ||||
| Return On Asset | 0.0184 |
CME Group Leadership Team
Elected by the shareholders, the CME's board of directors comprises two types of representatives: CME inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CME. The board's role is to monitor CME's management team and ensure that shareholders' interests are well served. CME's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CME's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Richard Romeo, Managing Analysis | ||
| Jonathan JD, Senior Counsel | ||
| Hilda Piell, Chief Human Resource Officer, Senior Managing Director | ||
| Anita Liskey, Senior Communications | ||
| Jack Tobin, Chief Accounting Officer, Managing Director | ||
| Kendal Vroman, Chief Officer | ||
| Michel Everaert, MD EMEA | ||
| Jonathan Marcus, Senior Counsel | ||
| Derek Sammann, Senior Managing Director - Financial Products and Services | ||
| Sean Keating, MD Office | ||
| Julie Winkler, Senior Managing Director - Research and Product Development | ||
| Lynne Fitzpatrick, Chief Officer | ||
| Jill Harley, Managing Director | ||
| Terrence Duffy, Executive Chairman and President Member of Competitive Markets Advisory Council, Chairman of Executive Committee and Member of Strategic Steering Committee | ||
| Edward Gogol, Managing Solutions | ||
| John Peschier, Managing Relations | ||
| Jason Weller, Managing Strategy | ||
| Sunil Cutinho, President - CME Clearing | ||
| Julie Holzrichter, COO and Sr. Managing Director | ||
| Christopher Bowen, Chief MD | ||
| Michael Dennis, Global Income | ||
| Elizabeth Gisch, Managing Management | ||
| Suzanne Sprague, COO MD | ||
| Eileen Keeve, Managing Devel | ||
| Kevin Lennon, Managing Estate |
CME Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is CME a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.12 | ||||
| Return On Asset | 0.0184 | ||||
| Profit Margin | 0.57 % | ||||
| Operating Margin | 0.65 % | ||||
| Current Valuation | 83.53 B | ||||
| Shares Outstanding | 360.36 M | ||||
| Shares Owned By Insiders | 0.45 % | ||||
| Shares Owned By Institutions | 89.43 % | ||||
| Number Of Shares Shorted | 3.83 M | ||||
| Price To Earning | 32.83 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether CME Group is a strong investment it is important to analyze CME's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact CME's future performance. For an informed investment choice regarding CME Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CME Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Is Financial Exchanges & Data space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CME. If investors know CME will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CME listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.214 | Dividend Share 4.55 | Earnings Share 9.51 | Revenue Per Share 16.795 | Quarterly Revenue Growth 0.185 |
The market value of CME Group is measured differently than its book value, which is the value of CME that is recorded on the company's balance sheet. Investors also form their own opinion of CME's value that differs from its market value or its book value, called intrinsic value, which is CME's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CME's market value can be influenced by many factors that don't directly affect CME's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CME's value and its price as these two are different measures arrived at by different means. Investors typically determine if CME is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CME's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.